[go: up one dir, main page]

BR9913446A - Produtos de aglicona e métodos de uso - Google Patents

Produtos de aglicona e métodos de uso

Info

Publication number
BR9913446A
BR9913446A BR9913446-2A BR9913446A BR9913446A BR 9913446 A BR9913446 A BR 9913446A BR 9913446 A BR9913446 A BR 9913446A BR 9913446 A BR9913446 A BR 9913446A
Authority
BR
Brazil
Prior art keywords
glycoconjugates
methods
aglycone
products
aglycone products
Prior art date
Application number
BR9913446-2A
Other languages
English (en)
Inventor
Samuel Bogoch
Elenore S Bogoch
Original Assignee
Samuel Bogoch
Elenore S Bogoch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samuel Bogoch, Elenore S Bogoch filed Critical Samuel Bogoch
Publication of BR9913446A publication Critical patent/BR9913446A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

"PRODUTOS DE AGLICONA E MéTODOS DE USO". Glicoconjugados, composições terapêuticas contendo os glicoconjugados e métodos terapêuticos para o uso dos glicoconjugados são revelados, em particular, constituintes de peptídeos de aglicona 10B, que são epítopos imunogênicos responsáveis pelo reconhecimento de antígenos por parte do sistema imunológico, são fornecidos. Estes glicoconjugados são úteis na prevenção da ligação do vírus da gripe às células, no tratamento da esquizofrenia e no diagnóstico de doença viral crónica associada ao desenvolvimento do câncer.
BR9913446-2A 1998-09-04 1999-08-30 Produtos de aglicona e métodos de uso BR9913446A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/146,755 US6242578B1 (en) 1994-02-17 1998-09-04 Aglyco products and methods of use
PCT/US1999/019836 WO2000018351A2 (en) 1998-09-04 1999-08-30 Aglyco products and methods of use

Publications (1)

Publication Number Publication Date
BR9913446A true BR9913446A (pt) 2004-03-02

Family

ID=22518867

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9913446-2A BR9913446A (pt) 1998-09-04 1999-08-30 Produtos de aglicona e métodos de uso

Country Status (13)

Country Link
US (4) US6242578B1 (pt)
EP (2) EP1115418B1 (pt)
JP (2) JP2004515202A (pt)
KR (1) KR100451446B1 (pt)
CN (2) CN1328286C (pt)
AT (1) ATE406175T1 (pt)
AU (1) AU771836B2 (pt)
BR (1) BR9913446A (pt)
CA (1) CA2341763C (pt)
DE (1) DE69939430D1 (pt)
IL (3) IL141775A0 (pt)
NZ (4) NZ556151A (pt)
WO (1) WO2000018351A2 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176275B2 (en) * 1998-09-04 2007-02-13 Samuel Bogoch Anthrax and small pox replikins and methods of use
DE10034712A1 (de) * 2000-07-17 2002-02-07 Arimedes Biotechnology Gmbh Verbrückte Glykokonjugate
US7420028B2 (en) * 2001-03-27 2008-09-02 Samuel Bogoch Replikins and methods of identifying replikin-containing sequences
US7442761B2 (en) * 2003-06-06 2008-10-28 Samuel Bogoch Replikin peptides and uses thereof
US7189800B2 (en) * 2001-03-27 2007-03-13 Samuel Bogoch Replikin peptides in rapid replication of glioma cells and in influenza epidemics
US7452963B2 (en) * 2001-03-27 2008-11-18 Samuel Bogoch Replikin peptides and antibodies therefore
WO2002085093A2 (en) 2001-03-27 2002-10-31 Samuel Bogoch Replikin peptides and uses thereof
KR100906102B1 (ko) * 2001-03-27 2009-07-07 사무엘 보고치 레플리킨 펩타이드 및 그의 이용
US7894999B2 (en) 2001-03-27 2011-02-22 Samuel Bogoch Systems and methods for identifying Replikin Scaffolds and uses of said Replikin Scaffolds
US7774144B2 (en) * 2001-10-26 2010-08-10 Samuel Bogoch System and method for identifying complex patterns of amino acids
JP2006500001A (ja) * 2001-07-09 2006-01-05 ボゴーク，サミュエル レプリキンペプチドとその使用
NZ553983A (en) 2001-07-09 2009-03-31 Samuel Bogoch Replikin peptides and uses thereof
US7306919B1 (en) 2001-10-31 2007-12-11 Thornthwaite Jerry T Antigen-antibody cancer recognition system
CN100556546C (zh) * 2003-02-13 2009-11-04 贝克顿·迪金森公司 在血液收集过程中去除成分的装置及其使用
US8494781B2 (en) * 2003-06-06 2013-07-23 Samuel Bogoch Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds
US9254315B2 (en) 2004-04-28 2016-02-09 Samuel Bogoch Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds
US9002652B1 (en) * 2005-01-27 2015-04-07 Institute For Systems Biology Methods for identifying and using organ-specific proteins in blood
CA2598381A1 (en) 2005-02-16 2006-08-24 Samuel Bogoch Replikin peptides and uses thereof
US9820986B2 (en) * 2005-03-04 2017-11-21 Taiwan Hopaz Chems, Mfg. Co., Ltd. Glycopeptide compositions
JP2006288670A (ja) * 2005-04-11 2006-10-26 Terumo Corp カテーテル
US8050871B2 (en) * 2006-10-24 2011-11-01 Samuel Bogoch Method of predicting influenza outbreaks by correlating an increase in replikin count in shrimp white spot syndrome virus and/or taura syndrome virus
US20090017052A1 (en) * 2007-01-18 2009-01-15 Samuel Bogoch Methods of determining lethality of pathogens and malignancies involving replikin peak genes
US20100105634A1 (en) * 2007-03-07 2010-04-29 Cargill, Incorporated Use of glucosamine as a mental and physical stress recovery enhancer and a performance enhancer
US9408902B2 (en) * 2007-05-30 2016-08-09 Samuel Bogoch Synthetic replikin peptides against pathogenic infection of invertebrates in aquaculture
US20090269367A1 (en) * 2008-04-23 2009-10-29 Samuel Bogoch Methods and compounds for mitigating pathogenic outbreaks using replikin count cycles
US20100144589A1 (en) * 2008-08-08 2010-06-10 Samuel Bogoch Methods of predicting cancer lethality using replikin counts
US9233148B2 (en) 2009-01-09 2016-01-12 Samuel Bogoch Replikin-based compounds for prevention and treatment of influenza and methods of differentiating infectivity and lethality in influenza
US9320784B2 (en) 2009-08-07 2016-04-26 Samuel Bogoch Peptides shared among lethal cancers and therapeutic compositions comprising said peptides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4298590A (en) * 1975-02-25 1981-11-03 Samuel Bogoch Detection of malignant tumor cells
US4840915A (en) * 1975-02-25 1989-06-20 Brain Research, Inc. Method for diagnosing malignant tumors
US4041146A (en) * 1975-05-01 1977-08-09 General Electric Company Method for detection of biological particles
US4486538A (en) * 1978-07-07 1984-12-04 Samuel Bogoch Detection of malignant tumor cells
US5280113A (en) 1989-08-16 1994-01-18 Monsanto Company Method for producing synthetic N-linked glycoconjugates
GB9202219D0 (en) 1992-02-03 1992-03-18 Connaught Lab A synthetic heamophilus influenzae conjugate vaccine
EP0812191B1 (en) * 1995-04-11 2005-07-20 Samuel Dr. Bogoch Peptides for the treatment of cancer

Also Published As

Publication number Publication date
EP1115418A2 (en) 2001-07-18
NZ556151A (en) 2009-03-31
US20040077532A1 (en) 2004-04-22
WO2000018351A2 (en) 2000-04-06
KR20010072517A (ko) 2001-07-31
NZ544362A (en) 2008-05-30
EP1115418B1 (en) 2008-08-27
US6638505B2 (en) 2003-10-28
IL192679A (en) 2011-10-31
EP1990058A1 (en) 2008-11-12
CA2341763A1 (en) 2000-04-06
JP2011087589A (ja) 2011-05-06
IL192679A0 (en) 2009-02-11
WO2000018351A3 (en) 2000-07-13
EP1115418A4 (en) 2004-06-09
NZ510921A (en) 2004-09-24
CA2341763C (en) 2014-01-21
US20030023047A1 (en) 2003-01-30
US7381411B2 (en) 2008-06-03
US20080241859A1 (en) 2008-10-02
CN1324258A (zh) 2001-11-28
AU5698699A (en) 2000-04-17
IL141775A (en) 2008-11-26
NZ533511A (en) 2006-08-31
CN1328286C (zh) 2007-07-25
AU771836B2 (en) 2004-04-01
US6242578B1 (en) 2001-06-05
KR100451446B1 (ko) 2004-10-06
DE69939430D1 (de) 2008-10-09
ATE406175T1 (de) 2008-09-15
CN101096382A (zh) 2008-01-02
JP2004515202A (ja) 2004-05-27
IL141775A0 (en) 2002-03-10

Similar Documents

Publication Publication Date Title
BR9913446A (pt) Produtos de aglicona e métodos de uso
DE69637642D1 (de) Und kombinierte zusammensetzungen und deren verwendung
BRPI0010612B8 (pt) vacinas
TR199801722T2 (xx) Peptit imm�nojenler.
ATE314095T1 (de) Virusähnliche partikel zur induktion von autoantikörpern
BR0207283A (pt) Anticorpos anti-egfr modificados com imunogenicidade reduzida
MY103182A (en) Vaccines against acquired immune deficiency syndrome.
PL366575A1 (pl) Kompozycje oraz sposoby leczenia i diagnozowania raka jajnika
WO1998008542A3 (en) Compounds and methods for treatment and diagnosis of mycobacterial infections
GB2255093A (en) Hiv-1 core protein fragments
IL106968A0 (en) Potentiation of immunogenic response
BRPI0508813B8 (pt) vacinas líquidas de combinação com baixa dose de conjugado de hib
NZ505834A (en) Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use
WO2001079259A8 (en) Javelinization of protein antigens to heat shock proteins
PT868522E (pt) Virus recombinante de poxvirus - virus da peritonite infecciosa felina, suas composicoes e metodos para a sua preparacao e utilizacao
DE68915046D1 (de) Haemophilus influenzae Typ B Polysaccharid-Aussermembranprotein-Konjugat als Impfstoff.
ATE375514T1 (de) Zusammensetzungen und methoden zur detektion einer trypanosoma cruzi infektion
EP1820514A3 (en) Therapeutic compositions that produce an immune response by altering the antigen
ATE310750T1 (de) Verotoxin b untereinheit zur immunisierunug
DK0852623T3 (da) Nukleinsyremolekyler kodende for proteiner, som medierer adhæsionen af Neisseria-celler til humane celler
BRPI0409321A (pt) antìgeno hìbrido, competição e método para induzir uma resposta imune para um agente infeccioso ou antìgeno de tumor, método para tratar uma doença infecciosa ou cáncer, e, peptìdeo
BR9905780A (pt) Antìgenos vacinais de leptospira para prevenção da laptospirose
SE8803062D0 (sv) Sequential polypeptides endowed with immunological activity
DK0542895T3 (da) Krydsreaktiv influenza A immunisering
BR0213554A (pt) Timosina para aumento da imunização genética

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13, 25 E 37 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 16A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2321 DE 30-06-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.